A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The primary aim is to establish a prospective cohort of patients with plasma cell disorders (PCDs). All of the hospitalized PCD patients who are willing to sign the informed consent form (ICF) will be included in this study. Clinical characteristics, treatment options and responses will be collected. Peripheral blood, bone marrow aspirate and urine samples before and after the treatment will banked for future research. Our team will focus on the clinical and pathological features of PCDs, the correlation between the minimal residual disease (MRD) status and prognosis, and the role of Tumor Microenvironment (TME) in the pathogenesis and progress of PCDs.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzona diagnoza zaburzenia komórek plazmatycznych
- •Pacjent hospitalizowany w Pierwszym Szpitalu Uniwersytetu Pekińskiego
- •Podpisana świadoma zgoda pacjenta na uczestnictwo w badaniu
✗ Disqualifies
- •Poważne choroby towarzyszące, które mogą zagrażać życiu
Simplified criteria — AI translation
Trial details
- Last updated (source)
- September 16, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Peking University First Hospital
Beijing, China
Trial contact
Bo Tang, PhD
Yujun Dong, M.D.
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/17/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.